antidepressant + placebo

This entry refers to the combination of an antidepressant drug and a placebo, typically as used in clinical trial settings for major depressive disorder or other depressive conditions. In randomized controlled trials (RCTs), patients are assigned to receive either an active antidepressant medication or a placebo (an inert substance with no pharmacological activity) to assess the efficacy and safety of the drug. The "antidepressant + placebo" combination is not a therapeutic regimen but rather represents the two arms commonly compared in clinical research. Antidepressants act through various mechanisms depending on their class, such as selective serotonin reuptake inhibition, norepinephrine reuptake inhibition, or modulation of other neurotransmitter systems. Placebo effects arise from patient expectations and psychological factors rather than direct pharmacological action. Meta-analyses show that both antidepressants and placebos can produce significant improvements in depression scores; however, the magnitude of improvement is generally greater with active medication—especially in more severe cases[2][3][5]. The response rate to placebos can be substantial (often 30–40%), highlighting the importance of expectation and study design[1][4][5]. Antidepressants demonstrate additional benefit over placebo primarily in patients with higher baseline severity[2][3][5].